Patricia L Allen bought $500k of ZBIO
director at Zenas BioPharma, Inc.. 19,860 shares at an average of $25.16, traded Feb 12, 2026, filed Feb 13, 2026.
Score components
- +15RoleDirector
- +18Trade size$500k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +8Price context40% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-015342, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 12, 2026 | POpen-market purchase Common Stock | +5,000 | $23.77 | $119k | 5,000 | Feb 13, 2026 |
| Feb 12, 2026 | POpen-market purchase Common Stock | +5,700 | $24.34 | $139k | 10,700 | Feb 13, 2026 |
| Feb 12, 2026 | POpen-market purchase Common Stock | +5,000 | $26.50 | $133k | 15,700 | Feb 13, 2026 |
| Feb 13, 2026 | POpen-market purchase Common Stock | +4,160 | $26.36 | $110k | 19,860 | Feb 13, 2026 |
Related signals
Other insiders at Zenas BioPharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 67Notable | Zenas BioPharma, Inc. | Hongbo Lu director | $1.5M 75,000 shares | +22% | |
| 71Notable | Zenas BioPharma, Inc. | Leon O Moulder Jr Chief Executive Officer | $1.0M 54,000 shares | +3% | |
| 60Notable | Zenas BioPharma, Inc. | Hongbo Lu director | $585k 25,985 shares | +8% | |
| 81Strong | Zenas BioPharma, Inc. | Leon O Moulder Jr Chief Executive Officer | $1.0M 57,000 shares | +16% | |
| 64Notable | ZBIObuy Zenas BioPharma, Inc. | Leon O Moulder Jr Chief Executive Officer | $1.6M 100,000 shares | +38% | |
| 58Moderate | Zenas BioPharma, Inc. | Patrick G Enright director | $2.3M 117,255 shares | +7% | |
| 50Moderate | Zenas BioPharma, Inc. | Sr One Capital Management, LLC owner | $2.4M 126,315 shares | +11% | |
| 58Moderate | Zenas BioPharma, Inc. | Jason Raleigh Nunn director | $1.2M 63,158 shares | +6% | |
| 62Notable | Zenas BioPharma, Inc. | Fairmount Funds Management LLC director | $6.0M 316,219 shares | +17% | |
| 58Moderate | ZBIObuy Zenas BioPharma, Inc. | Hongbo Lu director | $6.0M 321,983 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.